Clinical trials: Atopic Skin
Atopic Dermatitis
5-Year Safety Study of Pimecrolimus Cream 1% in Infants 3 - 12 Months of Age With Mild to Moderate Atopic Dermatitis
The primary purpose of this study is to investigate the safety of pimecrolimus cream 1% in the long-term treatment (up to 5 years) of atopic dermatitis (eczema) in patients less than 12 months of age compared to topical…
- Trial name
- NCT00120523
- Testing
- Pimecrolimus, Topical corticosteroids
- Where
- 31 sites in United States, Germany
- Volunteers
- 2,418 people
- Sponsor
- MEDA Pharma GmbH & Co. KG
Atopic Dermatitis
A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis
This open-label study will evaluate the long-term efficacy and safety of baricitinib in adult participants with moderate to severe atopic dermatitis (AD).
- Trial name
- BREEZE-AD6 (NCT03559270)
- Testing
- Baricitinib
- Where
- 74 sites in United States, Canada and 1 more
- Volunteers
- 374 people
- Sponsor
- Eli Lilly and Company
Pruritus, Atopic Dermatitis
Blinded, Randomized Study Evaluating Aurstat Versus Control in the Treatment of Atopic Dermatitis Associated Pruritus
To demonstrate the ability of Aurstat to reduce pruritus in subjects with mild to moderate atopic dermatitis. Efficacy results will be based on subject assessment, IGA, and photographic evidence based on ordinal scales for…
- Trial name
- AUR0613 (NCT01905631)
- Testing
- Aurstat Anti-Itch Hydrogel (Aurstat)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The Center for Clinical and Cosmetic Research
Dermatitis, Atopic, Dermatitis
Effect of Benralizumab in Atopic Dermatitis
Atopic Dermatitis (AD), also known as eczema, is a common skin disease characterized by itchy lesions. The prevalence of AD has increased over the past few decades, with 15-30% of children and 2-10%of adults being affected.
- Conditions
- Dermatitis, Atopic, Dermatitis, Eczema, Skin Diseases
- Trial name
- NCT03563066
- Testing
- Benralizumab
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- McMaster University
Atopic Dermatitis
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3)
The purpose of the study is to assess the efficacy and safety of ruxolitinib cream in children with Atopic Dermatitis. This is a randomized, double-blind, Vehicle Controlled study.
- Trial name
- NCT04921969
- Testing
- Ruxolitinib, Vehicle Cream
- Where
- 67 sites in United States, Canada
- Volunteers
- 330 people
- Sponsor
- Incyte Corporation
Psoriasis, Eczema
Neuroskin Forte for Dry Skin Relief in Eczema and Psoriasis
The purpose of this study is to assess the efficacy of Neuroskin Forte in relieving the symptoms of dry skin in adults with psoriasis or eczema.
- Trial name
- NCT00143819
- Testing
- Neuroskin Forte
- Volunteers
- 13 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Atopic Dermatitis
Comparison Trial of OPA-15406 Ointment in Pediatric Patients With Atopic Dermatitis
To demonstrate the superiority of the investigational medicinal product (IMP; 0.3% OPA-15406 ointment, 1% OPA-15406 ointment, or vehicle) to the vehicle when administered twice daily for 4 weeks using success rate in…
- Trial name
- NCT03911401
- Testing
- 0.3% OPA-15406, 1% OPA-15406
- Where
- Japan
- Volunteers
- 251 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Atopic Dermatitis
Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTEND
The purpose of this extension trial is to evaluate the long-term safety of tralokinumab.
- Trial name
- NCT03587805
- Testing
- Tralokinumab
- Where
- 309 sites in United States, Belgium and 9 more
- Volunteers
- 1,672 people
- Sponsor
- LEO Pharma
Atopic Dermatitis (AD)
Study of Ruxolitinib Cream in Adolescents With Atopic Dermatitis
The purpose of this study is to evaluate the long-term safety and tolerability of ruxolitinib cream in adolescents with Atopic Dermatitis (AD).
- Trial name
- NCT05456529
- Testing
- Ruxolitinib Cream
- Where
- 38 sites in United States, Canada and 1 more
- Volunteers
- 103 people
- Sponsor
- Incyte Corporation
Atopic Dermatitis
Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis
The primary objective of the study is to evaluate the efficacy of REGN3500 monotherapy compared with placebo treatment in adult patients with moderate-to-severe Atopic dermatitis (AD).
- Trial name
- NCT03736967
- Testing
- REGN3500, Dupilumab, REGN3500 + Dupilumab Combo
- Where
- 66 sites in United States, Belgium and 5 more
- Volunteers
- 206 people
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis
A Multi-omics Disease Signature Trial in Adult Patients With Moderate to Severe AD
This clinical trial will investigate the effectiveness and safety of a new active ingredient (LEO 138559) in the treatment of moderate to severe atopic dermatitis (AD). It is given by subcutaneous injection.
- Trial name
- NCT05470114
- Testing
- LEO 138559, Dupixent®
- Where
- Austria
- Volunteers
- 13 people
- Sponsor
- LEO Pharma
Atopic Dermatitis
A Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis
The purpose of this study is to evaluate the safety and efficacy of lebrikizumab compared with placebo in participants with moderate-to-severe atopic dermatitis.
- Trial name
- NCT03443024
- Testing
- Lebrikizumab
- Where
- 58 sites in United States
- Volunteers
- 280 people
- Sponsor
- Eli Lilly and Company
Dermatitis, Contact
A Study To Assess Safety And Effectiveness Of Medrol In Contact Dermatitis In Indian Patients
This study will be a prospective, non-interventional, single arm and open label study, in patients with contact dermatitis requiring systemic steroid therapy with a purpose to obtain the real life effectiveness and tolerability…
- Trial name
- NCT00929981
- Testing
- Tablet Methylprednisolone (4 or 16 mg)
- Where
- 4 sites in India
- Volunteers
- 80 people
- Sponsor
- Pfizer
Atopic Dermatitis
Targeted Investigation of Microbiome Elimination
The purpose of this study is to examine the pharmacokinetics or survival of new product containing commensal infection fighting bacteria, on the skin of patients with Atopic Dermatitis (AD), after a single application.
- Trial name
- TIME-1 (NCT05177328)
- Testing
- S. hominis A 9 Product
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dermatitis, Atopic, Dermatitis
A Study of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroids in Japanese Participants With Moderate-to-Severe Atopic Dermatitis
The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in combination with a topical corticosteroids in Japanese participants with atopic dermatitis.
- Conditions
- Dermatitis, Atopic, Dermatitis, Eczema, Skin Diseases
- Trial name
- ADhere-J (NCT04760314)
- Testing
- Lebrikizumab, Topical Corticosteroid
- Where
- 37 sites in Japan
- Volunteers
- 286 people
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis, Pruritus
B244 Topical Spray for the Treatment of Pruritus in Adults With a History of Atopic Dermatitis
This is a double-blind, randomized, vehicle-controlled study to assess the efficacy, safety, and tolerability of 2 doses of B244 for the treatment of pruritus in adults with a history of atopic dermatitis.
- Trial name
- NCT04490109
- Testing
- B244, Vehicle
- Where
- 56 sites in United States
- Volunteers
- 547 people
- Sponsor
- AOBiome LLC
Atopic Dermatitis (AD)
Targeted Microbiome Transplant in Atopic Dermatitis
The purpose of this study is to examine the safety and effectiveness of a new therapy, commensal lotion containing infection fighting bacteria, on decreasing or eliminating the infection causing bacteria found on the skin of…
- Trial name
- NCT03151148
- Testing
- TMT Lotion
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Atopic Dermatitis
Safety and Efficacy of CD5024 0.3% Cream in Subjects With Atopic Dermatitis
Exploratory, multi-centric, randomized, vehicle-controlled, investigator-blind, parallel group study, involved participants with chronic lesions of Atopic Dermatitis (AD) to evaluate the local and systemic safety of CD5024 0.3%…
- Trial name
- NCT03250624
- Testing
- CD5024 0.3% cream
- Where
- 5 sites in Canada
- Volunteers
- 63 people
- Sponsor
- Galderma R&D
Atopic Dermatitis
Validation of the Short-term Antimicrobial Action of Transplanted Bacteria
Unlike healthy control skin, the skin of patients with atopic dermatitis (AD) is frequently colonized by Staphylococcus aureus (S. aureus), putting these patients at increased risk of S. aureus skin infections.
- Trial name
- NCT01959113
- Testing
- Autologous Microbiome Transplant
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of California, San Diego
Atopic Dermatitis, Eczema
Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
There is a lack of prospective scientific data on the regular use of moisturizers in patients at risk of developing atopic dermatitis.
- Conditions
- Atopic Dermatitis, Eczema, Asthma, Food Allergies
- Trial name
- NCT01577628
- Testing
- Lipikar Balm AP
- Where
- 4 sites in United States, Canada
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Cosmetique Active International